Facioscapulohumeral Muscular Dystrophy (FSHD) is a common form of muscular dystrophy with an extremely complex genotype. A molecular detection requires the accurate sizing of a very large repeat region in the subtelomeric region of chr 4, a correct determining of the pathogenic vs non-pathogenic allele, and the distinction between the chromosome 4 repeat and an almost identical repeat on chr 10 not related to the disease. Molecular methods fail to do so, and hence a cumbersome, imprecise Southern Blot is currently used to molecularly diagnose this disease. The Bionano EnFocus FSHD Analysis performs the entire detection automatically, and validation studies have shown perfect concordance with the gold standard method.
- Clinical Research /
- EnFocus™ FSHD analysis
Facioscapulohumeral Muscular Dystrophy (FSHD) is typically caused by a contraction of the D4Z4 repeat array on chromosome 4 (chr 4). Measuring the length of the repeat array accurately is critical but only possible with labor-intensive Southern Blots using radioactive labeling. Bionano EnFocus™ FSHD analysis is a simple workflow based on genome imaging and enables accurate measurement of the D4Z4 array on chr 4 in just 3 days.
Replace outdated Southern Blots with Bionano
Bionano EnFocus FSHD analysis is a streamlined reliable molecular method to measure the number of D4Z4 repeats. It has 100% concordance to Southern blot for D4Z4 repeat array measurement in cell lines from FSHD positive individuals. In addition, it differentiates between permissive 4qA and non-permissive 4qB haplotypes and distinguishes the D4Z4 array present on chr4 from the partially homologous D4Z4 array present on chr10.